Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pralle

Showing results (191-200 of 207) with videos related to

Pageof 21
Sort By:
Leukemia|April 1, 1997
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study GroupR Hehlmann, A Willer, H Heimpel, et al.
The New England Journal of Medicine|August 16, 1979
Heterogeneity of diffuse "histiocytic" lymphoma according to the Kiel classificationP Meusers, H Bartels, G Brittinger, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Leukemia Research|January 1, 1982
Multicentre study on intensified remission induction therapy for acute myeloid leukemiaT Büchner, D Urbanitz, B Emmerich, et al.
Leukemia|July 30, 2003
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trialR F Schlenk, A Benner, F Hartmann, et al.
Ebiomedicine|July 30, 2023
Neuronal actin cytoskeleton gain of function in the human brainKinga Szigeti, Ivanna Ihnatovych, Nicolás Rosas, et al.
Leukemia|April 22, 2005
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemiaR F Schlenk, U Germing, F Hartmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemiaRüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Pageof 21

Showing results (191-200 of 207) with videos related to

Sort By:
Pageof 21
Leukemia|April 1, 1997
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study GroupR Hehlmann, A Willer, H Heimpel, et al.
The New England Journal of Medicine|August 16, 1979
Heterogeneity of diffuse "histiocytic" lymphoma according to the Kiel classificationP Meusers, H Bartels, G Brittinger, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Leukemia Research|January 1, 1982
Multicentre study on intensified remission induction therapy for acute myeloid leukemiaT Büchner, D Urbanitz, B Emmerich, et al.
Leukemia|July 30, 2003
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trialR F Schlenk, A Benner, F Hartmann, et al.
Ebiomedicine|July 30, 2023
Neuronal actin cytoskeleton gain of function in the human brainKinga Szigeti, Ivanna Ihnatovych, Nicolás Rosas, et al.
Leukemia|April 22, 2005
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemiaR F Schlenk, U Germing, F Hartmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemiaRüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Pageof 21